Evidence map›Paper›PMID 41122189›Full record

ReviewMediterranean journal of rheumatology2025

The N-of-1 Trials and where to use them in Rheumatology.

Maria G Grammatikopoulou, Arriana Gkouvi, Sotirios G Tsiogkas, Theodora Simopoulou, Dimitrios G Goulis, Dimitrios P Bogdanos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mediterranean journal of rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Maria G GrammatikopoulouDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece.
Arriana GkouviDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece.
Sotirios G TsiogkasDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece.
Theodora SimopoulouDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece.
Dimitrios G GoulisUnit of Reproductive Endocrinology, 1 Department of Obstetrics and Gynaecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios P BogdanosDepartment of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, Larissa, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: N-of-1 trials constitute single-patient, randomised, crossover and often, double-blind clinical trials, where each patient serves as his/her own control. The implementation of Methods: For the purpose of this review, we searched PubMed and clinicaltrials.gov for Results: N-of-1 trials can facilitate clinical decisions and evaluate the efficacy of medications, lifestyle interventions, or adjuvant treatments (i.e. for pain), while focusing on disease-specific outcomes or comorbidities (cachexia, obesity, etc.). In this review, the advantages and limitations of Conclusions: Employing the

Indexed as

evidence-based medicinefatiguefibromyalgiaindividualised careindividualised medicinen-of-1osteoarthritispainrandomised controlled trialrheumatoid arthritis

Identifiers

PMID41122189
PMCPMC12536745

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.